세계의 유행성이하선염 백신 시장 : 동향, 예측, 경쟁 분석(-2030년)

Mumps Vaccine Trends and Forecast

The future of the global mumps vaccine market looks promising with opportunities in the pediatric clinic, hospital, and NGO markets. The global mumps vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are high prevalence and morbidity of mumps infection, growing demand for efficient and safe mumps vaccines, and rising government support for mumps vaccination programs.

Lucintel forecasts that combinational is expected to witness highest growth over the forecast period due to its advantages like convenience and cost-effectiveness.

Within this market, pediatric clinic will remain the largest segment due to significant application of mumps vaccine among children.

North America is expected to witness highest growth over the forecast period.

Emerging Trends in the Mumps Vaccine Market

Developing trends in the mumps vaccine market are testament to changing vaccine technology, increasing coverage efforts, and growing awareness about the prevention of mumps.

• Technological Advancement: Innovations in the technology of formulation and delivery systems contribute to enhancing the efficacy and safety profiles of the vaccines against mumps.
• Increased Vaccination Coverage: Increased vaccination coverage through public health campaigns and integration into routine immunization programs has been expanding protection against mumps across the globe.
• Booster Doses: Increasingly, there is emphasis on booster doses, which are very crucial for long-term immunity and help neutralize mumps outbreaks associated with waning vaccine protection.
• Global Health Initiatives: Global health initiatives of collaboration on access to and coverage of vaccines have increased in recent years, particularly for low- and middle-income countries.
• Addressing Vaccine Hesitancy: Public education and communication are enhanced to address vaccine hesitancy and improve vaccination rates.

This in turn would act as a key driver of change within the mumps vaccine market, where the efficacy of the vaccines would increase, along with coverage and the overall public health response.

Recent Developments in the Mumps Vaccine Market

The development in the mumps vaccine market is focused on improving vaccines, policy changes, and the expansion of vaccination.

• Development of Improved Vaccine Formulations: New formulations developed for vaccines are intended to enhance their safety and efficacy profiles, enabling their improved protective function against complications due to mumps infections.
• Booster Doses a New Priority: Booster doses added to the schedules will also keep such issues at bay as waning immunity of populations and recent resurgences of mumps outbreaks.
• Expansion of Immunization Programs: There is increased effort toward integrating the mumps vaccine into routine immunization programs, especially in most deprived areas and low-income countries.
• Improved Vaccine Surveillance: With this, the improvement in monitoring and surveillance systems enables the effective tracking of cases and the effectiveness of vaccines against the disease to inform evidence-based public health responses.
• Global Health: Global health collaborations and initiatives have shifted focus toward ensuring access to and coverage of vaccines, particularly in those areas of the world where vaccination rates remain low.

Accordingly, the improvements described enhance the efficiency and coverage of mumps vaccination programs, thus improving global control of the infection.

Strategic Growth Opportunities for Mumps Vaccine Market

The strategic growth opportunities in the mumps vaccine market include an increasing demand for vaccines, expanded immunization programs, and technological advancements.

• Routine Immunization Programs: The expanding mumps vaccine into routine immunization programs creates growth opportunities through increased coverage and protection from early childhood onwards.
• Booster Dose Programs: Increased implementation and expansion of booster dose programs can help to address issues of waning immunity and improve long-term protection against mumps.
• Public Health Campaigns: Expanding the sphere of public health campaigns toward creating awareness and overcoming vaccine hesitancy will present potential ways to increase vaccination rates, hence lowering the rate of infectious diseases.
• Global Health Partnerships: Collaboration with global health partners may be helpful in extending the reach and equity of vaccine access and distribution in low- and middle-income countries. This will likely ensure market growth and further global health improvement.
• Technological Innovations: Investment in new vaccine technologies and delivery systems offers new possibilities to improve vaccine efficacy and safety, leading to wider market acceptance of the vaccines.

All these strategic opportunities enhance access, efficacy, and coverage for mumps vaccines, thus driving market growth.

Mumps Vaccine Market Driver and Challenges

Various technological, economic, and regulatory factors are affecting the mumps vaccines market, which includes both driving and challenging factors.

The factors responsible for driving the mumps vaccine market include:

1. Technological Advancement: The development of new innovative vaccines and delivery systems raises the bar on vaccine safety and efficacy, thereby driving the market.

2. Increased Vaccination Awareness: Increasing awareness toward vaccination against mumps diseases is leading to a rise in vaccination rates.

3. Government Policies: Favorable government policies and allocations toward vaccination programs spur the market to grow further, easing access to the vaccines.

4. Global Health Initiative: International collaborations and health initiatives help improve vaccine availability and access, particularly within resource-poor settings

Challenges in the mumps vaccine market are:

1. Vaccine Supply Challenges: Disruptions in supply chains seriously affect the availability and access to vaccines, thus impacting vaccination programs and ultimately market stability.

2. Vaccine Distribution Challenges: Logistical challenges related to vaccine distribution, particularly in far-flung areas, act as a major hindrance toward effective immunization and market growth.

3. Ensuring Regulatory Compliance: The complexity of regulatory requirements is challenging and may impact market entry and product availability.

These drivers and challenges influence the shaping of the mumps vaccine market by their effect on vaccine development, coverage, and overall public health outcomes.

List of Mumps Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mumps vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mumps vaccine companies profiled in this report include-

• MedImmune
• Johnson & Johnson
• Merck
• Sanofi
• Serum Institute of India
• Bavarian Nordic
• Astellas Pharma India
• CSL
• Emergent BioSolutions
• GlaxoSmithKline

Mumps Vaccine by Segment

The study includes a forecast for the global mumps vaccine by product type, age group, end use, and region.

Mumps Vaccine Market by Product Type [Analysis by Value from 2018 to 2030]:

• Monovalent
• Combinational
• Divalent
• Trivalent
• Others

Mumps Vaccine Market by Age Group [Analysis by Value from 2018 to 2030]:

• Pediatric
• Adult

Mumps Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Pediatric Clinic
• Hospitals
• NGOs
• Others

Mumps Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Mumps Vaccine Market

The advancement of vaccine technology, regional health policies, and growing global health initiatives are driving development in the recent mumps vaccine market.

• United States: The country has recorded developments in relation to advancements in the formulation of vaccines and the uptake of booster doses as a response to the outbreaks recorded in the country lately. It is also putting in place an improved monitoring and vaccination campaign to try and stem the decline in vaccine coverage that contributes to the resurgence of the mumps virus infection.
• China expanded the mumps vaccination program by incorporating it into the general immunization program. Much attention is also paid to the improvement of vaccine coverage in rural areas and vaccination hesitancy through public education.
• Germany designed new vaccination guidelines and increased accessibility to vaccines within the broader strategy to control mumps. Another significant task for this country is to ensure adequate vaccinations by promoting public health campaigns.
• India: The mumps vaccine market is growing continuously as India tries to cover more and more ground in terms of vaccination outreach in its most under-resourced areas. There are continuing activities aimed at the integration of the mumps vaccine into the national immunization schedule, while the improvement of logistics regarding vaccine delivery is also being pursued.
• Japan: Japan has revised its guidelines for vaccination by recommending booster doses of the mumps vaccine. Japan is also strengthening surveillance systems for vaccines in order to monitor better the incidence of the disease and effective performance of vaccines.

Features of the Global Mumps Vaccine Market

Market Size Estimates: Mumps vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Mumps vaccine market size by product type, age group, end use, and region in terms of value ($B).

Regional Analysis: Mumps vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, age groups, end uses, and regions for the mumps vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mumps vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the mumps vaccine market size?

Answer: The global mumps vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for mumps vaccine market?

Answer: The global mumps vaccine market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the mumps vaccine market?

Answer: The major drivers for this market are high prevalence and morbidity of mumps infection, growing demand for efficient and safe mumps vaccines, and rising government support for mumps vaccination programs.

Q4. What are the major segments for mumps vaccine market?

Answer: The future of the mumps vaccine market looks promising with opportunities in the pediatric clinic, hospital, and NGO markets.

Q5. Who are the key mumps vaccine market companies?

Answer: Some of the key mumps vaccine companies are as follows:

• MedImmune
• Johnson & Johnson
• Merck
• Sanofi
• Serum Institute of India
• Bavarian Nordic
• Astellas Pharma India
• CSL
• Emergent BioSolutions
• GlaxoSmithKline

Q6. Which mumps vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that combinational is expected to witness highest growth over the forecast period due to its advantages like convenience and cost-effectiveness.

Q7. In mumps vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the mumps vaccine market by product type (monovalent, combinational, divalent, trivalent, and others), age group (pediatric and adult), end use (pediatric clinic, hospitals, NGOs, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Mumps Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Mumps Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Mumps Vaccine Market by Product Type
  • 3.3.1: Monovalent
  • 3.3.2: Combinational
  • 3.3.3: Divalent
  • 3.3.4: Trivalent
  • 3.3.5: Others
• 3.4: Global Mumps Vaccine Market by Age Group
  • 3.4.1: Pediatric
  • 3.4.2: Adult
• 3.5: Global Mumps Vaccine Market by End Use
  • 3.5.1: Pediatric Clinic
  • 3.5.2: Hospitals
  • 3.5.3: NGOs
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Mumps Vaccine Market by Region
• 4.2: North American Mumps Vaccine Market
  • 4.2.1: North American Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
  • 4.2.2: North American Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
• 4.3: European Mumps Vaccine Market
  • 4.3.1: European Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
  • 4.3.2: European Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
• 4.4: APAC Mumps Vaccine Market
  • 4.4.1: APAC Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
  • 4.4.2: APAC Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
• 4.5: ROW Mumps Vaccine Market
  • 4.5.1: ROW Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
  • 4.5.2: ROW Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Mumps Vaccine Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Mumps Vaccine Market by Age Group
  • 6.1.3: Growth Opportunities for the Global Mumps Vaccine Market by End Use
  • 6.1.4: Growth Opportunities for the Global Mumps Vaccine Market by Region
• 6.2: Emerging Trends in the Global Mumps Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Mumps Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Mumps Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: MedImmune
• 7.2: Johnson & Johnson
• 7.3: Merck
• 7.4: Sanofi
• 7.5: Serum Institute of India
• 7.6: Bavarian Nordic
• 7.7: Astellas Pharma India
• 7.8: CSL
• 7.9: Emergent BioSolutions
• 7.10: GlaxoSmithKline